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 ABSTRACT              
Objective: Patients undergoing major orthopaedic surgery face considerable risk of venous 
thromboembolic complications (VTE). Fondaparinux (Arixtra®) is a new antithrombotic 
agent, which is indicated for VTE prophylaxis. This report presents cost-effectiveness 
analysis of fondaparinux compared with enoxaparin, the most common prophylaxis of VTE. 
The cost-effectiveness of short-term duration (one week) prophylaxis as well as prolonged 
prophylaxis (four weeks) with fondaparinux versus enoxaparin are examined here.  
Methods: The models used in the analyses are developed to simulate the impact of 
prophylaxis with fondaparinux compared with enoxaparin after major orthopaedic surgery. 
The short-term model examines the cost-effectiveness of fondaparinux in patients undergoing 
total knee replacement, total hip replacement and hip fracture surgery. The second model 
examines the impact of extended prophylaxis following hip fracture surgery, and extrapolates 
the results in patients undergoing total hip replacement. 
Data: The analysis is based on Norwegian data, which include about 55.000 patients who 
underwent major orthopaedic surgery in the period from 1999 to 2001. All cost estimates in 
the models are based on the Norwegian unit costs.  
Results: The results from clinical outcomes show that in general, fondaparinux compared with 
enoxaparin is the more effective drug in terms of preventing VTE-events (deep vein 
thrombosis, fatal and not fatal pulmonary embolism). By day 90 after surgery, fondaparinux is 
expected to avoid additional 194 VTE-events after total knee replacement, 146 events after 
total hip replacement and 249 events after hip fracture surgery per 10.000 patients compared 
to enoxaparin. Extended prophylaxis with fondaparinux prevents 217 and 273 VTE-events per 
10.000 patients following total hip replacement and hip fracture surgery respectively 
compared to enoxaparin at 90 days follow-up time. 
Short-term prophylaxis with fondaparinux is also more cost-effective than enoxaparin. From 
day 30 onward, fondaparinux is cost saving after major orthopaedic surgeries. Fondaparinux 
is also highly cost saving with respect to incremental costs per VTE avoided, VTE-related 
deaths avoided and costs per life-year gained. However, in the case of extended prophylaxis, 
fondaparinux is the higher cost alternative relative to enoxaparin, but the cost difference 
decreases over time. The sensitivity analyses confirmed the robustness of the main results.  
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1.  Introduction 
1.1 Background 
Venous thromboembolism (VTE) complications such as deep-vein thrombosis (DVT) and 
pulmonary embolism (PE) are major causes of morbidity and mortality. The risk of 
developing VTE is due to post-operative immobility as well as the effects of surgical trauma 
on the coagulation system (Clagett et al., 1995). Patients undergoing major orthopaedic 
surgery face considerable risk of VTE, unless they receive prophylactic treatment. In fact, 
without prophylaxis the risk of developing DVT within 7-14 days after major orthopaedic 
surgery is 50%-60% in patients undergoing major orthopaedic surgery, while the risk of 
developing PE is 7-11% (Geerts et al., 2001). While DVT is the most common form of VTE, 
PE has a higher mortality risk.  
Despite the routine prophylactic treatment after major surgery, patients are still at risk of VTE 
complications. VTE can be symptomatic or clinically silent. In fact, the incidence of DVT is 
silent in a majority of patients. DVT symptoms appear on average 27 days after total hip 
replacement, 36 days after hip fracture surgery and 17 days after total knee replacement 
(Dahl, et al., 1997). The clinical diagnosis is not always reliable in detecting DVT, and 
commonly available non-invasive tests are not sensitive enough for diagnosis of all 
asymptomatic DVT. Undetected and hence untreated VTE will put the patient at risk for later 
complications. As the risk of VTE persists up to 3 months after surgery, patients at high risk 
for postoperative VTE may benefit from extended prophylaxis (e.g, an additional 3 weeks 
after the first 7 to 10 days) (Kearon, 2003).   
1.2 Aim of the study  
The incidence of hip fracture in Norway is high and increasing (Falch et al., 1993). During the 
years 1999, 2000 and 2001, a total of 54,988 major orthopaedic surgeries were performed in 
Norway1. The majority of these operations were due to hip fracture surgery (HFS) (50%) and 
total hip replacement (THR) (40%), while 10% were due to total knee replacement (TKR).  
The prevalence of VTE is high in patients undergoing major orthopaedic surgery (Geerts et 
al., (2001). In Norway, the most common prophylactic drugs for prevention of VTE after 
                                                 
1 Norwegian National Register of Hospital Patients.  
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major orthopaedic surgery are low-molecular-weight heparins (e.g., enoxaparin) (Finsen 
2002). Despite current prophylaxis regimens, venography-proven VTE remains significant in 
patients receiving low-molecular-weight heparin; up to 16% with elective hip replacement, 
27% with hip fracture surgery, and 31% with knee replacement surgery (Geerts et al., (2001). 
Given the large number of major orthopaedic surgeries in Norway and costs related to 
treatment of VTE, determining the most cost-effective prophylaxis against thromboembolism 
is an important issue.  
Fondaparinux (Arixtra®) belongs to a new class of synthetic antithrombotic agents that 
prevents clot formation and is indicated for prophylaxis of VTE in patients undergoing 
orthopaedic surgeries. The objective of this study is to present cost-effectiveness analyses of 
short-term and long-term duration prophylaxis with fondaparinux versus enoxaparin after 
major orthopaedic surgery. The short-term prophylaxis refers to the prophylaxis during the 
inpatient period (e.g. 1 week), while the long-term duration refers to extended prophylaxis 
after the discharge from the hospital (e.g. additional 3-4 weeks). The outcome of the cost-
effectiveness analysis is important for the health authorities concerning price and 
reimbursement decisions, and for physicians at hospitals concerning inclusion of this new 
drug in treatment praxis.  
The study is based on international simulation models developed for determining the costs 
and effects of fondaparinux versus enoxaparin. The study provides estimates of the incidence 
of clinical VTE and VTE-related deaths, treatment costs per patient, incremental cost per 
VTE-event avoided, cost per death avoided and cost per life-year gained. The study does not 
discuss subjects such as improved life quality or increased productivity for patients who avoid 
VTE by receiving fondaparinux. Data used in the analysis are provided by the Norwegian 
Register of Hospital Patients (NPR), which include about 55.000 major orthopaedic surgery 
patients. Further, all estimates of unit costs in the model are based on costs within the 
Norwegian Diagnosis Related Group (DRG) and other relevant costs for year 2004. 
1.3 Fondaparinux as prophylaxis against VTE  
Fondaparinux is indicated for prophylaxis of VTE in patients undergoing orthopaedic 
surgeries and was launched in Norway in June 2002 (ATC-code B01AX05). The following 
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sections present a literature overview over Phase III clinical trials of fondaparinux and its 
pharmacoeconomic evaluations compared with enoxaparin. 
 
1.3.1 Efficacy of fondaparinux 
Four Phase III clinical trials have compared fondaparinux with enoxaparin in reducing the risk 
of VTE after major orthopaedic surgery: Turpie et al. (2002) “the Ephesus study”; Lassen et 
al. (2002) “the Pentathlon 2000 study”; Bauer et al. (2001) ”the Pentamaks study” and 
Eriksson et al. (2001) “the Penthifra study”. In all four trials, patients in fondaparinux group 
received injections of 2,5mg postoperatively. In Pentathlon 2000 and Pentamaks, patients 
treated with Enoxaparin received postoperative injections of 30mg twice daily (US practice), 
while in Ephesus and Penthifra 40mg enoxaparin was given once daily (European practice), 
starting preoperatively. Ephesus and Pentathlon 2000 were conducted for total hip 
replacement. The outcome from Pentathlon 2000 was that fondaparinux was as effective as 
Enoxaparin in reducing risk of VTE. In the Ephesus study fondaparinux was found to be more 
effective. Pentamaks and Penthifra compare fondaparinux with enoxaparin in patients 
undergoing major knee surgery and hip fracture surgery, respectively. The outcome of these 
studies was that fondaparinux lowered the risk of VTE by at least 55% compared to 
enoxaparin.  
Turpie et al. (2002b) present a meta-analysis of data from the four Phase III clinical trials 
mentioned above. These four studies enrolled 7344 patients over age 18, from North America, 
Australia and Europe. The analysis showed that fondaparinux reduced the incidence of VTE 
by day 11 by over 50% (95% CI, 45,8 to 63,1%; P<0.001) compared to enoxaparin. There 
were no differences between fondaparinux and enoxaparin in rates of fatal bleeding, bleeding 
in a critical organ or bleeding leading to reoperation. The incidence of major bleeding 
(bleeding index of 2≥ )2 was 1% higher with fondaparinux compared with enoxaparin (2,7% 
vs 1,7%; P=0.008). A post hoc analysis showed that the bleeding risk was related to the 
timing of the first dose. The bleeding risk was highest when fondaparinux was administered 
within the first 6 hours postoperatively. However, when fondaparinux was injected after the 
first 6 hours postoperatively, there was no difference in bleeding rates between fondaparinux 
and enoxaparin.  
                                                 
2 Bleeding index of 2≥  is defined as the number of units of packed red blood cells or whole blood transfused 
plus the pre-bleeding minus post-bleeding hemoglobin values (g/dL). 
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Recent clinical trials indicate that extending prophylaxis with fondaparinux from one to four 
weeks after hip fracture surgery reduced the risk of VTE by 96% (95% CI, 87,2% to 99,7%; 
P<0,001). Extended prophylaxis was associated with a lower incidence of proximal, total or 
distal DVT and fewer symptomatic VTEs than prophylaxis for one week (Eriksson, et al., 
2003). Fondaparinux was generally well tolerated and there was no significant increase in the 
incidence of bleeding events with prolonged prophylaxis compared with standard duration 
(short-term) prophylaxis. 
 
1.3.2 Cost-effectiveness studies of fondaparinux 
Short-term duration prophylaxis 
Pharmacoeconomic studies of fondaparinux prophylaxis have been performed in several 
countries. These studies were undertaken from the perspective of the healthcare payers, and 
compared the costs and effects of prophylaxis with fondaparinux versus enoxaparin. The main 
results from some of these studies are presented in the following. In all studies mentioned 
here, fondaparinux was found to be more effective than enoxaparin in preventing VTE-events.  
Gordois et al. (2003) is based on data from United Kingdom. The study concludes that using 
fondaparinux in UK reduces costs by £27 per patient relative to enoxaparin over a period of 
five years post-surgery. Lundkvist et al. (2003) analyse the cost-effectiveness of fondaparinux 
based on Swedish unit costs. The results showed that fondaparinux was cost saving and more 
effective than enoxaparin after TKR and HFS and had costs per prevented VTE of about €239 
after THR. Bjorvatn and Kristiansen (2003 and 2005) analyse the cost-effectiveness of 
fondaparinux based on Norwegian unit costs. The analysis included 55.000 patients who 
underwent major orthopaedic surgery from 1999 to 2001. The results showed the cost-
effectiveness of fondaparinux per avoided VTE-event from day 30 onward compared to 
enoxaparin. Recently, several non-European studies have been published, concluding the cost-
effectiveness of fondaparinux compared with enoxaparin; two US-studies by Sullivan et al. 
(2004) and Wade et al. (2004), and a Canadian-study by Dranitsaris, et al. (2004).   
Extended duration prophylaxis 
The cost-effectiveness of extended prophylaxis (28 days) with fondaparinux after hip fracture 
surgery has been studied in the US (Sullivan and Kwong, 2003a; 2003b). These studies 
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concluded that extended prophylaxis with fondaparinux instead of enoxaparin would avoid 
204 VTE-events (including 82 deaths) per 10.000 patients by day 30 after surgery, and 278 
VTE-events (including 111 deaths) per 10.000 patients by day 90 after hip fracture surgery. 
Further, fondaparinux was found to be cost saving compared to enoxaparin from day 90 
onward.  
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2.  Method 
The study is based on simulation models that have been developed in order to examine the 
cost-effectiveness of fondaparinux compared with enoxaparin for both short-term and 
extended duration prophylaxis. The short-term model examines the cost-effectiveness of 
fondaparinux in patients undergoing total knee replacement, total hip replacement and hip 
fracture surgery. The second model examines the impact of extended prophylaxis following 
hip fracture surgery, and extrapolates the results in patients undergoing total hip replacement. 
 Costs of VTE-related care (DVT and PE) during both inpatient and outpatient period, post-
thrombotic syndrome (PTS) and major haemorrhage are incorporated in the models. The 
models can be run for a hypothetical cohort of patients undergoing either surgical procedure 
over various time periods up to 5 years following surgery. The main outcomes of the models 
are the incidence of clinical VTE and VTE-related deaths, and treatment costs per patient. In 
addition, the extended duration model estimates the incremental cost per VTE-event avoided, 
incremental cost per death avoided and incremental cost per life-year gained. In order to make 
comparisons between the results of the short-term and extended duration analyses, we also 
provide own estimates of the incremental costs per VTE-event avoided, death avoided and 
incremental cost per life-year gained for the short-term prophylaxis.   
2.1  Model structure 
The design of the main model is based in part on an earlier decision-analytic model of the 
outcomes, clinical management, and costs of VTE and PE that was developed in the mid-
1980's (Oster, et al., 1987). In the original model, patients were assumed to be at risk of 
developing VTE only during the inpatient period. In the fondaparinux model, VTE risk is 
assumed to continue for a period of 90 days following surgery. Some patients are therefore 
assumed to develop VTE after hospital discharge.  
The short-term duration model estimates the clinical outcomes and costs of VTE prophylaxis 
in patients undergoing hip fracture surgery, and total knee and hip replacement, developed by 
Gordois et al. (2003) and Sullivan et al. (2002). The structure of the extended duration model 
is close to the short-term duration model. This model estimates the clinical outcomes and 
costs of extending VTE prophylaxis in patients undergoing hip fracture surgery, and 
extrapolates the results in patients undergoing total hip replacement.  
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An underlying assumption of the models is that patients undergoing either orthopaedic 
surgery are at risk of DVT and PE, and that either short-term duration or extended duration 
prophylaxis with fondaparinux or enoxaparin reduces the risk of VTE. In the models, patients 
are considered to be at risk of clinical VTE events for a period of 90 days following surgery. 
From day 90 and up to 5 years after surgery, patients are assumed to be at risk for recurrent 
VTE events (fatal or non-fatal) and post-thrombotic syndrome (PTS). Patients with clinically 
detected and confirmed DVT and PE are assumed to be at risk of recurrent VTE and PTS. 
Those with subclinical DVT only are assumed to be at risk of PTS. Finally, the model 
discriminates between two distinct periods: an acute phase, which begins with surgery and 
ends 90 days thereafter; and a chronic phase, which begins on day 91 and ends five years after 
the initial surgical procedure.   
The decision tree model can be divided into four major time frames: the initial 7-day period 
which corresponds to the short-term duration prophylaxis, the day 7 to day 30 time frame 
which corresponds to the extended duration prophylaxis, day 30 to day 90, when patient is 
still at risk of clinical VTE, and the day 90 to year 5 period which includes the chronic phase. 
The possible outcomes at each node are as follows.   
1.  Day 7 
• Symptomatic (clinical) VTE events (DVT, fatal and non-fatal PE) 
• Bleeding events (major bleedings) 
 
2. Day 30  
• Venographically detected (sub-clinical) DVT  
• Symptomatic (clinical) VTE events (DVT, fatal and non-fatal PE) 
• False-positive VTE events 
• Bleeding events (major bleedings) 
 
 
3. Day 90  
• Symptomatic (clinical) VTE events (DVT, fatal and non-fatal PE) 
• False-positive VTE events 
• Recurrent VTE (fatal and non-fatal) 
 
4. Year 1  - Year 5 
• Recurrent VTE (fatal and non-fatal) 
• Post-thrombotic syndrome (PTS) 
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Figure 1 illustrates the graphic representation of the model. 
Figure 1: Graphic representation of the model 
 
Source: Policy Analysis Inc (2003) 
 
2.2 Estimation of model probabilities 
Event probabilities in the models are derived from fondaparinux Phase III trial data (Eriksson, 
2001; Bauer, 2001; Lassen, 2002; Turpie, 2002; Eriksson, 2003) and data in published 
literature sources. For details on model probabilities see Gordois et al. (2003) and Sullivan et 
al. (2004). Estimation of the underlying probabilities in the extended duration model is 
described in further details in Appendix A. See also Tables 1 to 3 in Appendix A for all model 
probabilities. 
2.3 Estimation of resource use and costs 
Estimates of VTE-related resource use and associated costs as well as costs of prophylaxis in 
the models are country dependant parameters and include estimates for: 
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• Prophylaxis: including cost of drug, administration and monitoring. 
• Confirmation and treatment of clinical DVT and PE, while inpatient and after 
discharge. 
• Suspected but unconfirmed DVT and PE, while inpatient and after discharge; costs of 
tests and physician visits. 
• Major Hemorrhage: bleeding index ≥2 3 (prophylaxis related) and clinically relevant. 
• Post thrombotic syndrome (PTS): acute and chronic phase. 
2.4 Measures 
The models can be run for hypothetical cohorts of either 1.000 or 10.000 patients. Model 
results are calculated for multiple time points including surgery to hospital discharge, Day 30, 
Day 90, Year 1 and Year 5 after sugery. The models generate estimates of the expected 
incidence of symptomatic VTE events (DVT and PE), as well as the expected number of 
VTE-related deaths. The short-term duration model estimates the expected costs of VTE-
related care for TKR, THR, and HFS, while the extended duration model generates estimates 
of the expected costs of VTE-related care for THR and HFS, incremental cost per VTE event 
avoided, incremental cost per death avoided and incremental cost per life-year gained. 
                                                 
3 Number of units of packed red blood cells or whole blood transfused, plus [prebleeding minus postbleeding 
hemoglobin values in g/dl]. 
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3.  Estimation of resource use and unit costs used in the analysis4 
3.1 Analysis of data  
Data in the analysis were selected from the complete files of the Norwegian National Register 
of Hospital Patients (NPR), where each record represents a single completed stay in hospital 
for a single patient. The sample contains data for the years 1999, 2000, and 2001. During 
these years a total of 54.988 major orthopaedic surgeries were performed in Norway. Patients 
were identified by operation codes: NFBxx for total hip replacement, NGBxx for total knee 
replacement or NFJxx for hip fracture surgery. The majority of these operations were due to 
HFS (50%) and THR (40%), while 10% were due to total knee replacement.  
In the sample, patients who had undergone other major surgeries before TKR, THR and HFS, 
patients under age of 18 and patients with DVT, PE or bleeding as main diagnosis were 
excluded from the analysis. Further, patients with multiple traumas affecting more than one 
organ system, or who were under 18 years of age, were excluded, resulting in a sample of 
51.555 patients. The distribution of procedures in the sample was 10.7% TKR, 40.1% THR, 
and 49.2% HFS. 
Table 3.1 shows the distribution of patients who underwent TKR, THR and HFS in the years 
1999, 2000 and 2001. The average ages of patients in the sample were 69.73 years for TKR, 
71.62 years for THR and 78.78 years for HFS. 
Table 3.1 Distribution of patients (hospital stays)  
1999 2000 2001 Total
Total knee replacement 1 504 1 844 2 160 5 508
Total hip replacement 6 352 6 800 7 545 20 697
Hip fracture surgery 8 422 8 319 8 609 25 350
Total  16 286 16 964 18 316 51 555
Source: Bjorvatn and Kristiansen (2003) 
                                                 
4 Section 3.1 is based on the analysis of data presented in SNF-report no 13/03 by Bjorvatn and Kristiansen 
(2003).  
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Secondary diagnoses of PE, DVT or bleeding in hospital were identified by ICD-10 codes. PE 
was indicated by ICD-code I26, DVT by ICD-code I80 and Bleeding by ICD-codes T81.0, 
I60, I61, I62, RO4, R58, K62.5 or K92.2. Bleeding is in terms of the fondaparinux-model: 
prophylaxis related and given a fairly wide definition. An alternative indicator, narrower in 
scope, may be only ICD-codes K62.5 or K92.2, related with gastrointestinal bleeding. This 
indicator would be more treatment related (related to anticoagulation treatment of DVT or 
PE).   
Table 3.2 shows the total number of hospital stays (patients) and average length of stay for 
patients who underwent major orthopaedic surgery from 1999 to 2001. In addition, the Table 
presents the total number of patients and average length of stay for those who had a secondary 
diagnosis of DVT, PE or bleeding during their initial stay in hospital (inpatient period). For 
instance, 13, 51 and 62 patients were treated for a secondary diagnosis of PE after TKR, THR 
and HFS respectively, while 37, 73 and 42 patients were treated for a secondary diagnosis of 
DVT after TKR, THR and HFS.  
 
Length of stay during initial hospitalisation 
A log-linear regression model was constructed to predict the effect on length of stay during 
hospitalization. The incidences of PE, DVT or bleeding were represented as explanatory 
dummy variables in the regression model. The model also included age and sex of the patients 
as explanatory variables.  
 
The length of stays in hospital for the three procedures in the sample was as follows; Patients 
with TKR stayed on average 12.5 days in hospital, while patients with THR and HFS stayed 
on average 12.62 and 10.81 days in hospital, respectively, see Table 3.2. 
During the inpatient period, 37 patients developed DVT after TKR, while 73 and 42 patients 
developed DVT following THR and HFS respectively. The additional length of stay for these 
patients was estimated to 4.69 days after TKR, 4.51 days after THR and 5.98 days after HFS.  
The number of patients who developed a secondary diagnosis of PE is 13 after TKR, 51 after 
THR and 62 after HFS. The estimated additional length of stay for these patients was 3.49 
days after TKR, 1.97 days after THR and 5.66 days after HFS. The additional length of stay 
LOS for prophylaxis-related bleeding for the entire sample was estimated at 5.92 days.  
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Table 3.2 Hospital stays from 1999 to 2001; Inpatient period 
 Total knee 
replacement 
Total hip 
replacement 
Hip fracture 
surgery 
Total number of patients 5 508 20 697 25 350
     No secondary diagnosis 5 448 20 486 25 110
     Secondary diagnosis of DVT 37 73 42
     Secondary diagnosis of PE 13 51 62
     Secondary diagnosis of Bleeding  10 87 136
Average length of stay (days) 12.5 12.62 10.81
     No secondary diagnosis 12.44 12.54 10.74
     Extra days by s.d. of DVT 4.69 4.51 5.98
     Extra days by s.d. of PE  3.49 1.97 5.66
     Extra days, s.d. of Bleeding, prophylaxis related 1   5.92 5.92 5.92
     Extra days, s.d. Bleeding              4.67 4.67 4.67
s.d: Secondary diagnosis  
1 For model simulation purposes, length of stay for the entire sample is applied. 
Source: Bjorvatn & Kristiansen (2003).  
 
Length of stay after initial hospitalisation (readmissions)  
The length of stays for patients readmitted with a main diagnosis of PE, DVT or bleeding was 
calculated separately, as mean days. Table 3.3 presents the number of hospital stays (patients) 
and average length of stay for patients who underwent TKR, THR or HFS and readmitted the 
hospital with a secondary diagnosis of DVT, PE or bleeding within 90 days. For instance, 
number of readmitted patients with a secondary diagnosis of DVT was 7 following TKR, 53 
following THR and 86 following HFS. The mean LOS for readmitted patients with DVT was 
5.86 days following TKR, 5.25 days following THR and 5.77 days following HFS. 
After TKR, THR and HFS, 6, 35 and 50 patients readmitted the hospital with a secondary 
diagnosis of PE respectively. The average length of hospital stay for these patients was 7.17, 
11.17 and 9.6 days respectively.   
Separate estimates of additional length of stay related to bleeding caused by treatment of DVT 
or PE were not justified by the available data. For modelling purposes, however, separate 
mean calculations were made for patients readmitted within 90 days. For readmissions with 
treatment-related bleeding, mean length of stay for the entire sample was 4.67 days. 
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Table 3.3 Hospital stays from 1999 to 2001; Readmissions with secondary diagnosis within 
90 days 
 Total knee 
replacement
Total hip 
replacement 
Hip fracture 
surgery
Total number of patients 20 110 221
     DVT 7 53 86
     PE 6 35 50
     Bleeding  7 22 85
Average length of stay (days)   
     DVT 5.86 5.25 5.77
     PE 7.17 11.17 9.60
     Bleeding, treatment-related1 4.67 4.67 4.67
1 For model simulation purposes, length of stay for the entire sample is applied. 
Source: Bjorvatn & Kristiansen (2003).   
 
3.2 Estimation of other parameters used in the analysis  
Estimation of life expectancy 
In the analysis, we will provide estimates of costs per life-year gained for patients. Therefore, 
it is necessary to calculate estimates of the additional life years for patients undergoing major 
orthopaedic surgeries. Table 3.4 presents the expected additional life years for the general 
population (men and women) in Norway. The age category shown in the Table is from 69 to 
79 years.  
Table 3.4 Expected additional life years in Norway 
Age Men Women 
69 13.41 16.59 
70 12.74 15.77 
71 12.06 14.99 
72 11.42 14.25 
73 10.77 13.49 
74 10.17 12.76 
75  9.58 12.03 
76             9.00 11.34 
77  8.46 10.66 
78 7.94   9.97 
79 7.42   9.34 
Source: Norwegian population statistics 2002, Statistics Norway. 
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In the model, the average life expectancy of patients undergoing major orthopaedic surgery 
patients is assumed to be the same as in the general population matched for the age and sex of 
the patients in the sample. In calculating the expected additional life years among patients 
undergoing THR, TKR and HFS, we have weighted the population data in the sample by 
patients’ age and sex. As indicated in Table 3.5, the average age of THR patients in the 
sample is 71.62 years, where 72% of the patients are female. The expected additional life 
years among THR patients weighted by age and sex is calculated to 13.73 years. Hence, the 
average life expectancy for THR patients in the model was set to 85.35 years. The same 
reasoning applies for TKR patients. Hip fracture surgery is associated with substantial 
morbidity and should be reduced by 25% compared with the general population matched for 
age and sex with the studied cohort (Braitwait, 2003). For HFS patients, the expected 
additional life years is calculated to 8.91 years. A reduction by 25% will change the expected 
additional life years to 6.68. Therefore, the life expectancy for HFS patients was set to 85.46 
years.  
 
Table 3.5 Expected additional life years by type of surgery 
Surgery Age (mean years) Female patients Expected additional life years
TKR 69.73 70% 15.07 
THR 71.62 72% 13.73 
HFS 78.78 71%  6.68 
 
 
Duration of prophylaxis 
In the model, we assume 7 days of prophylaxis during the inpatient period. Fondaparinux is 
indicated for extended duration prophylaxis following total hip replacement and hip fracture 
surgery. Fondaparinux can be administered for a period of 31 days in total. Therefore, we 
assume extended prophylaxis for 24 days (i.e. after hospital discharge). Further, we assume 
that 25% of the patients require assistance from a nurse for the injection of fondaparinux or 
enoxaparin after discharge from the hospital. All estimates of the parameters used in the 
model are presented in Table 3.6. 
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Table 3.6 Parameter estimates for the analyses, by type of procedure 
 Total knee 
replacement 
Total hip 
replacement 
Hip fracture 
surgery 
Length of initial prophylaxis (days) 7 7 7 
Length of extended prophylaxis (days) Not relevant 24 24  
Length of inpatient stay (days) 12.5     12.62    10.81 
Average age of patients (years) 69.73     71.62    78.78 
Average life expectancy (years) 84.40    85.35   85.46 
Outpatient visit by nurse (%) Not relevant   25%  25% 
 
3.3 Costs of procedures and treatments   
Costs of procedures 
In the analysis, estimates of costs for inpatients were based on current prices for year 2004 
within the Norwegian Diagnosis Related Group (DRG) system. In this system, patients are 
classified in one group only, per stay in hospital5. The method for DRG cost calculations in 
Norway is top-down. The total operational costs of hospitals are decomposed into cost units, 
and cost units are attributed to specific DRGs by applying keys that reflect the historical use 
of resources and length of stay within each DRG. 
The relevant DRG-categories for DVT, PE and bleeding were identified by listing 
occurrences of actually applied categories by patients with one of these diagnoses as the main 
diagnosis, in the total sample. For bleeding, the pair of DRG-categories 174 and 175 covered 
38.2% and 61.8% of all stays respectively. The actual treatment costs in hospital for DVT, PE 
and bleeding based on DRG-prices, average length of stay per DRG and average costs per day 
per DRG are provided in Table 3.7. The results from the estimates of additional length of stay 
in hospital by secondary diagnosis showed variations in hospitalisation time among patients 
undergoing different surgical procedures. The average costs per day, together with the 
estimates of length of stay were used in estimating costs of treatment of DVT and PE after 
each surgical procedure.  
 
                                                 
5 The Norwegian guidelines for pharmacoeconomic analysis for drug reimbursement applications recommend 
official DRG-prices as cost inputs to analysis of hospital stays (Norwegian Medicines Agency, 2002). 
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Table 3.7 DRG-categories and total costs of treatment in hospital 
 DRG-
category 
Description 2004-cost, 
NOK 
Mean 
LOS 
Average cost 
per day, NOK 
DVT 128 Deep vein thrombophlebitis            27 098 5.44 4 981 
PE   78 Pulmonary embolism   46 243 9.18 5 037 
Bleeding  174 (38.2%), 
175 (61.8%) 
174: Gastrointestinal hemorrhage 
with complications  
175: Gastroin. hem. without 
compl.                                         
22 033 4.93 4 469 
DRG: Diagnosis-related groups 
LOS: Length of stay 
 
The total DRG rate for DVT or PE includes diagnosis and treatment according to standard 
medical practice, follow-up visits and INR monitoring (Dahl and Pleil, 2003). Costs were 
estimated separately following each surgical procedure depending on the estimates of length 
of stay in hospital.  
For the treatment of DVT and PE, we assumed one physician visit, drug treatment and 10 INR 
tests6 (personal communication with physician). The cost of one extra day at hospital was 
estimated based on the average net cost per hospitalisation day for DVT, and PE, i.e., 
exclusive of physician visit, drug costs and test costs. The costs of physician visits and 
diagnostic investigations were obtained from the price list for cost per outpatient clinic 
consultation and procedure provided by The Norwegian Ministry of Health, and information 
provided from The National Insurance Services. 
According to the Norwegian practice, DVT/PE is treated with either dalteparin og enoxaparin, 
supplemented by warfarin (Personal communication). For treatment of DVT and PE, we 
assumed enoxaparin administration for 5 days, followed by warfarin for 90 days in case of 
DVT, and 180 days in case of PE. The dose of enoxaparin was set to 150mg7. The warfarin 
dose depends on individual test results and varies between different patients. We consider a 
dose of 7,5mg warfarin to be the normal dose (2,5mg three times a day). The cost of 150mg 
enoxaparin is NOK41 per day8 (LIS price). The cost of 7,5mg of warfarin is NOK2.36 per 
day.  
                                                 
6 PT tests are not very common in Norway (Personal communication with physician). 
7 1mg per kg (depending on patient’s weight) times 2. Therefore, a daily dose for a patient with a weight of 75kg 
is 150mg. 
8 The price is based on a package of 10x1ml syringes (150mg). 
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For the assessment DVT after initial hospital stay, we assumed one physician visit and one 
diagnostic investigation; venography or ultrasound for DVT, and spiral computed tomography 
for PE (personal communication). For the assessment of suspected DVT while inpatient, we 
assumed only diagnostic investigations.  
There are several diagnostic methods for investigation of PE such as spiral-CT (Computed 
tomography), DSA (Digital Subtraction Angiography), and so on. We assumed one physician 
visit and one spiral-CT, which is the most common method for confirming PE after initial 
hospital stay. For the assessment of suspected PE during the inpatient period, we assumed 
only diagnostic investigations. 
The weighted mean from costs of DRG-pair 174 and 175 was chosen for both prophylaxis and 
treatment-related bleeding. The costs of treatment of post-thrombotic syndrome were 
estimated from a Swedish study of long-term consequences of VTE (Bergqvist et al., 1997). 
The study includes the costs of treating cellulites, chronic venous insufficiency, varicose veins 
and venous ulcer. This definition is compatible with the PTS risk assumptions in the Arixtra-
model. The distribution of the costs between acute and chronic was also based on the 
assumption that 25% of PTS-related costs would be accrued at the time of initial diagnosis, 
while the remaining costs would be distributed evenly over time. Costs were converted from 
Swedish kroner by using average exchange rates for year 2004. 
Prophylaxis costs 
In the model, we assume prophylaxis with enoxaparin (Klexane®) and fondaparinux 
(Arixtra®) for 7 days while inpatient, and extended prophylaxis for 24 days. The costs of both 
drugs are based on wholesale prices in Norway (LIS price and consumer price)9.  
The cost of one dose of 40mg enoxaparin once daily is NOK8 for the inpatient period (LIS 
price), and NOK 44.5 for the outpatient period (consumer price). The former price is based on 
a package of 50x0.4ml syringes, while the latter is based on a package of 10x0.4ml syringes. 
Enoxaparin is also available in packages containing 10 syringes, at NOK13.50 per unit. We 
have also conducted a sensitivity analysis based on this price in section 5. 
                                                 
9 Based on the price list provided by the manufacturer and The Norwegian Medicines Agency. 
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The cost of 2.5mg (0.5ml single-dose, 5mg/ml) fondaparinux once daily is NOK40.64 for the 
inpatient period (LIS price), and NOK108.59 for the outpatient period (consumer price). 
These prices are based on a package of 20x0.5ml syringes. 
Administration costs by nurse 
The cost of injection of fondaparinux or enoxaparin after discharge from hospital was set to 
NOK 35 (Personal communication with health care centre). Table 3.8 presents all unit cost 
estimates used in the analysis for each surgical procedure.  
Table 3.8  Unit cost estimates used in analyses by type of procedure, per patient, 2004 
prices, NOK   
 Total knee 
replacement 
Total hip 
replacement 
Hip fracture 
Surgery 
Fondaparinux per day  Inpatient           40.64           40.64           40.64 
Fondaparinux per day Outpatient         108.59         108.59         108.59 
Enoxaparin per day Inpatient        8         8        8 
Enoxaparin per day Outpatient         44.50         44.50         44.50 
Injection by nurse, 
Fondaparinux/Enoxaparin  
Outpatient Not relevant        35       35 
Treatment DVT  Inpatient 19 374 18 693 24 205 
Treatment DVT Post discharge 23 763 21 480 23 426 
Suspected DVT Inpatient 1   1 628    1 628   1 628 
Suspected DVT Post discharge2    2 818     2 818  2 818 
Treatment PE  Inpatient  15 291   9 521 23 562 
Treatment PE Post discharge  29 282 44 479 38 514 
Suspected PE Inpatient3     872       872     872 
Suspected PE Post discharge4   2 063  2 063  2 063 
Major Bleeding Prophylaxis-related   22 033 22 033 22 033 
Major Bleeding Clinically relevant  22 033 22 033 22 033 
Post thrombotic syndrome  Acute (first quarter)  8 739 8 739 8 739 
Post thrombotic syndrome  Chronic (per quarter) 1 380 1 380 1 380 
1 Ultrasound or venography 
2 Physician visit and Ultrasound or venography 
3 Spiral-DT 
4 Physician visit and Spiral-DT. 
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4. The results 
All analyses are conducted separetely for cohorts of 10.000 patients undergoing total knee and 
hip replacement, and hip fracture surgery. The model results are calculated for multiple time 
periods from surgery to hospital discharge, day 30, day 90, year 1 and year 5 after surgery. In 
section 4.1, the clinical outcomes and VTE-related cost outcomes of short-term (7 days) 
prophylaxis with fondaparinux versus enoxaparin are presented, while in section 4.2, the 
clinical outcomes and VTE-related cost outcomes of extended prophylaxis (24 days) with 
fondaparinux and enoxaparin are presented. 
4.1 Short-term prophylaxis (1 week) 
4.1.1 Clinical outcomes  
Table 4.1 presents the clinical outcomes of prophylaxis with fondaparinux versus enoxaparin 
for short-term prophylaxis. In a cohort of 10.000 patients undergoing TKR, THR, HFS, 
fondaparinux (Arixtra) is expected to avoid respectively 80, 33 and 51 DVT-events more than 
enoxaparin prior to hospital discharge. The corresponding figures for PE-events avoided, are 
34, 19 and 28. Finally, Arixtra prevents additional 12 deaths (fatal PE) after TKR, 3 deaths 
after THR and 11 deaths after HFS per 10.000 patients compared to enoxaparin.  
At longer follow-up times (30 days and 90 days after surgery) Arixtra is also expected to be 
more effective than enoxaparin. For instance, at day 90 following, Arixtra is expected to avoid 
additional 124, 87 and 132 DVT-events, and 53, 51 and 84 PE-events per 10.000 patients 
following TKR, THR and HFS respectively compared to enoxaparin. Finally, using 
fondaparinux avoids 17 more deaths after TKR, 8 more deaths after THR and 33 more deaths 
after HFS per 10.000 patients compared to enoxaparin. 
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Table 4.1 Short-term prophylaxis: Number of clinical VTE-events per 10.000 patients 
  DVT Non fatal PE Fatal PE Total 
Inpatient/Discharge 
TKR Arixtra  67 29 14 110 
 Enoxaparin 147 63 26 236 
 Difference -80 -34 -12 -126 
THR Arixtra  29 16 4 49 
 Enoxaparin 62 35 7 104 
 Difference -33 -19 -3 -55 
HFS Arixtra  43 25 12 80 
 Enoxaparin 94 53 23 170 
 Difference -51 -28 -11 -90 
30 days follow-up time 
TKR Arixtra  114 50 16 180 
 Enoxaparin 223 96 30 349 
 Difference -109 -46 -14 -169 
THR Arixtra  112 40 10 162 
 Enoxaparin 180 80 16 276 
 Difference -68 -40 -6 -114 
HFS Arixtra  195 69 36 300 
 Enoxaparin 302 134 63 499 
 Difference -107 -65 -27 -199 
90 days follow-up time 
TKR Arixtra  149 66 18 233 
 Enoxaparin 273 119 35 427 
 Difference -124 -53 -17 -194 
THR Arixtra  184 58 14 256 
 Enoxaparin 271 109 22 402 
 Difference -87 -51 -8 -146 
HFS Arixtra  314 97 51 461 
 Enoxaparin 446 181 84 711 
 Difference -132 -84 -33 -249 
Figures are rounded. 
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4.1.2 Cost outcomes  
In this section, treatment costs per patient, incremental costs per VTE avoided, costs per death 
avoided and costs per life-year gained are presented for different surgical procedures and at 
different time periods for short-term duration prophylaxis (7 days) with fondaparinux and 
enoxaparin. Costs are discounted at 3% per year. 
VTE-related cost outcomes 
Unit costs presented in Table 3.8 were used in simulations of the model. The results from the 
analysis of short-term prophylaxis with fondaparinux compared with enoxaparin are presented 
in Table 4.2. The results are reported for the three surgical procedures and different time 
periods. In the table, a negative number implies cost savings by fondaparinux, while a positive 
number implies that prophylaxis with fondaparinux involves added costs. 
Table 4.2  Short-term prophylaxis: VTE-related costs  per patient, NOK 
   Follow-up time 
Procedure Treatment Discharge 30 days 90 days 1 year 5 years
TKR Arixtra 1 081 1 357 1 577 1 780 2 428
 Enoxaparin 1 056 1 428 1 694 2 018 3 052
 
Difference 25 -70 -117 -238 -624
THR Arixtra 974 1 366 1 689 1 887 2 521
 Enoxaparin 826 1 379 1 797 2 044 2 830
 
Difference 148 -13 -108 -156 -310
HFR Arixtra 1 061 1 700 2 174 2 391 3 056
 Enoxaparin 1 023 1 930 2 530 2 827 3 736
 Difference 38 -230 -356 -436 -680
Figures may not sum because of rounding. 
Table 4.2 shows that at discharge fondaparinux (Arixtra) is the higher cost treatment after the 
three surgical procedures. For instance, among patients undergoing TKR, VTE-related costs 
per patient at hospital discharge are estimated to NOK1.081 for Arixtra and NOK1.056 for 
enoxaparin, which indicates added medication costs of NOK25 by using Arixtra. The longer 
is the follow-up time, the smaller is the cost disadvantage of Arixtra relative to enoxaparin. 
Indeed, from day 30 onward, Arxitra is cost saving after the three surgical procedures. For 
SNF Report No. 1/05 
 22
example, by day 30, Arixtra is cost saving by NOK70 after TKR, NOK13 after THR and 
NOK230 after HFS compared with enoxaparin.  
Incremental cost-effectiveness ratios 
Table 4.3 presents the incremental cost-effectiveness ratios. The results are presented as cost 
per clinical VTE avoided, cost per death avoided and cost per life-year gained by using 
fondaparinux. In the Table, negative numbers indicate cost savings by using fondaparinux. 
Table 4.3 Short-term prophylaxis: Incremental cost-effectiveness ratios per patient, NOK 
   Follow-up time 
Procedure  30 days 90 days 1 year 5 years
TKR Cost per VTE avoided -4 142 -6 031 - - 
 Cost per death avoided -50 000 -68 824 -140 000 -367 059 
 Cost per Life Year Gained -3 318 -4 567 -9 290 -24 357 
THR Cost per VTE avoided -1 140 -7 397 - - 
 Cost per death avoided -21 667 -135 000 -195 000 -387 500 
 Cost per Life Year Gained -1 578 -9 832 -14 202 -28 223 
HFS Cost per VTE avoided -11 588 -14 297 - - 
 Cost per death avoided -85 185 -107 879 -132 121 -206 061 
 Cost per Life Year Gained -12 752 -16 150 -19 779 -30 847 
 
Figures are rounded. 
The incremental cost effectiveness ratio per avoided VTE-event is the additional cost 
associated with treating with fondaparinux rather than enoxaparin, divided by the total 
number of avoided VTE-events. For instance, with TKR the cost savings of treatment with 
fondaparinux (cost difference) is NOK70 per patient at day 30, which for 10.000 patients 
amounts to NOK700.000 (Table 4.2), while the total number of avoided VTE-events is 169 
(Table 4.1). Hence, the incremental cost savings per avoided VTE-event is NOK4.142 at day 
30. By day 90, the cost savings increase to NOK6.031. The same reasoning applies for the 
other procedures. As evident from the Table, fondaparinux is also cost saving after total hip 
replacement and hip fracture surgery. In general, the cost savings per avoided VTE-event by 
using fondaparinux increase over time. 
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We calculated costs per death avoided by dividing the total cost difference between 
fondaparinux and enoxaparin by the difference in the total number of VTE-related deaths 
avoided. By day 30, fondaparinux avoids additional 14 deaths after TKR and 6 deaths after 
THR per 10.000 patients compared to enoxaparin. Hence, by day 30, cost savings per death 
avoided is NOK50.000 following TKR and NOK21.667 following THR.  Further, the number 
of deaths avoided with fondaparinux is greatest in HFS patients, where 27 more deaths are 
avoided. In case of HFS, fondaparinux reduces costs per death avoided by NOK85.185 by day 
30. As evident from the Table, cost savings by using Arixtra instead of enoxaparin increase 
over time. 
Finally, we calculated cost per life-year gained. As we see, using fondaparinux indicates 
significant cost savings already by day 30, with benefits increasing over time. For example, 
cost savings per life-year gained after TKR by day 30 are NOK3.318, while over a period of 5 
years these savings increase to NOK24.357. 
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4.2 Extended prophylaxis (24 days) 
4.2.1 Clinical outcomes   
For the extended prophylaxis, the results are shown for 30 days and 90 days after surgery in 
Table 4.4. For the 30 days follow-up time, fondaparinux is expected to prevent 101 DVT, 35 
non-fatal PE and 6 deaths per 10.000 patients after THR. After HFS, fondaparinux is expected 
to prevent 77 DVT, 45 PE and 82 deaths per 10.000 patients compared to enoxaparin. Hence 
in total, fondaparinux prevents 142 VTE-events after THR and 204 VTE-events after HFS per 
10.000 patients compared to enoxaparin. For the 90 days follow-up time, the corresponding 
figures are 217 and 273 avoided VTE-events in total per 10.000 patients. 
Table 4.4 Extended prophylaxis: Number of clinical VTE-events per 10.000 patients 
  DVT Non fatal PE Fatal PE Total 
30 days follow-up time 
THR Arixtra extended 48 17 3 68 
 Enoxaparin extended 150 51 9 210 
 Difference -101 -35 -6 -142 
      
HFS Arixtra extended 37 22 39 98 
 Enoxaparin extended 113 68 122 302 
 Difference -77 -45 -82 -204 
90 days follow-up time 
THR Arixtra extended 52 18 3 72 
 Enoxaparin extended 206 71 12 289 
 Difference -155 -53 -9 -217 
HFS Arixtra extended 38 23 41 102 
 Enoxaparin extended 141 84 150 376 
 Difference -103 -61 -110 -273 
Figures may not sum because of rounding. 
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4.2.2 Cost outcomes   
In this section, treatment costs per patient, incremental costs per VTE avoided, costs per death 
avoided and costs per life-year gained are presented for different surgical procedures and at 
different time periods for extended duration prophylaxis with fondaparinux and enoxaparin. 
Costs are discounted at 3% per year.  
VTE-related cost outcomes 
Unit costs estimates presented in Table 3.8 were used in simulations of the model. The results 
from these simulations are presented in Table 4.5 for the three surgical procedures. In the 
tables, a negative number implies cost savings by fondaparinux, while a positive number 
implies that prophylaxis with fondaparinux involves added costs. 
 
Table 4.5 Extended prophylaxis: VTE-related costs per patient, NOK 
 Follow-up time 
Procedure 30 days 90 days 1 year 5 years
THR Arixtra extended 4 162 4 282 4 297 4 351 
 Enoxaparin extended 2 692 3 015 3 111 3 446 
 Difference 1 469 1 266 1 186 905 
HFS Arixtra extended 4 247 4 353 4 369 4 426 
 Enoxaparin extended 3 196 3 510 3 665 4 217 
 Difference 1 051 843 704 208 
Figures may not sum because of roundings. 
Table 4.5 presents costs per patient for VTE-related care at different time periods for 
fondaparinux and enoxaparin. As we see, fondaparinux is the higher cost treatment alternative 
compared with enoxaparin. However, when the follow-up time increases, the cost difference 
between the two drugs decreases. For example, the cost difference between the two drugs at 
30 days follow-up time is NOK1.469 after total hip replacement, while at 5 years follow-up 
time this difference is expected to be NOK905. For hip fracture surgery, the cost difference 
between the drugs is NOK1.051 at discharge, and NOK208 at 5 years follow-up time. 
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Incremental cost-effectiveness ratios 
Table 4.6 presents the incremental cost-effectiveness ratios for extended prophylaxis with 
fondaparinux versus enoxaparin. 
Table 4.6 Incremental cost-effectiveness ratios per patient, NOK 
Procedure  30 days 90 days 1 year 5 years
THR Cost per VTE avoided 103 328 58 372 - - 
 Cost per death avoided 2 464 731 1 397 550 1 300 885 974 014 
 Cost per Life Year Gained 179 514 101 788 94 748 72 311 
HFS Cost per VTE avoided 51 485 30 838 - - 
 Cost per death avoided 127 958 76 983 64 159 18 904 
 Cost per Life Year Gained 19 155 11 524 9 605 2 844 
 
Extended prophylaxis with fondaparinux is more effective in preventing VTE-events than 
enoxaparin. For example, at the 30 days time period, extended prophylaxis with fondaparinux 
prevents an additional 142 VTE-events per 10.000 patients after total hip replacement (Table 
4.4). The difference in treatment costs by fondaparinux compared to enoxaparin is NOK1.469 
per patient (Table 4.5). Hence, the incremental cost per avoided VTE after THR is 
NOK103.328 at the 30 days time period10. At day 90, the cost per avoided VTE is NOK 
NOK58.372. 
At day 30, fondaparinux prevents an additional 204 VTE-events per 10.000 patients after hip 
fracture surgery compared to enoxaparin. In this case, the cost difference between 
fondaparinux compared to enoxaparin is NOK1.051 per patient. Therefore, the cost per 
avoided VTE after HFS is NOK51.485 at day 30. For the 90 days follow-up time, the 
incremental cost per avoided VTE is NOK30.838.   
As we see from Table 4.6, the cost per death avoided and cost per life-year gained decrease 
when the follow up time increases. Over a period of 5 years, cost per death avoided following 
HFS is expected to be NOK18.904, while cost per life-year gained is only NOK2.844. 
 
 
                                                 
10 Please notice that costs presented in Table 4.5, as well as number of avoided VTE-events, are rounded. 
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5. Sensitivity analyses  
Several sensitivity analyses were conducted in order to test the validity of the results. The 
analyses were performed on enoxaparin price (inpatient) and on fondaparinux price for 
outpatient treatment. 
5.1 Short-term prophylaxis 
Enoxaparin price (NOK13.50 per day)  
In the main analysis, the price of enoxaparin is set to NOK8 per unit (inpatient period). This 
price is based on a package of 50 syringes of 40mg enoxaparin at NOK400 (LIS price). 
Enoxaparin is also available at NOK135 for 10x40mg syringes, with a unit price at 
NOK13,50. A sensitivity analysis was conducted in order to test the impact of this price on 
our results. 
Results  
Table 5.1 presents the results of the sensitivity analysis for the short-term prophylaxis. Please 
notice that in the Table, only the cost difference between fondaparinux and enoxaparin for 
each surgical procedure is reported. A negative number implies cost savings by fondaparinux, 
while a positive number implies that prophylaxis with fondaparinux involves adde costs. 
Table 5.1 Sensitivity analysis: 
VTE-related cost difference between fondaparinux and enoxaparin, per patient, NOK 
Short-term prophylaxis Follow-up time 
 Discharge Day 30 Day 90 Year 1 Year 5
TKR Base case (enoxaparin, NOK8) 25 -70 -117 -238 -624
 Enoxaparin price: NOK13.50 -14 -109 -156 -277 -662
  
THR Base case (enoxaparin, NOK8) 148 -13 -108 -156 -310
 Enoxaparin price: NOK13.50 109 -52 -147 -195 -348
  
HFS Base case (enoxaparin, NOK8) 38 -230 -356 -436 -680
 Enoxaparin price: NOK13.50 -1 -269 -394 -474 -718
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The results from the sensitivity analysis show that when enoxaparin price is increased to 
NOK13,50 fondaparinux becomes cost saving after total knee replacement and cost neutral 
after total hip replacement already at discharge. From day 30 onward, it is also cost saving 
after total hip replacement. For example, in the main analysis (base case) at discharge, 
fondaparinux had added costs of NOK25 after TKR, while in the sensitivity analysis cost 
savings of NOK14 are achieved by using fondaparinux. By day 30, cost savings with 
fondaparinux relative to enoxaparin increase to NOK109 after TKR, NOK52 after THR and 
NOK269 after HFS.  
5.2 Extended prophylaxis  
Enoxaparin price (NOK13.50 per day)  
In the main analysis, the price of enoxaparin is set to NOK8 per unit (inpatient period) based 
on a package of 50 syringes of 40mg enoxaparin at NOK400. Enoxaparin is also available at 
NOK135 for 10x40mg syringes, with a unit price at NOK13.50. We conducted a sensitivity 
analysis was conducted in order to test the impact of this price on the results from the main 
analysis. 
Fondaparinux price, outpatient  
For the short-term prophylaxis, fondaparinux was cost saving already at discharge following 
total knee replacement and cost neutral following hip fracture surgery. For the extended 
prophylaxis, fondaparinux had higher medication costs relative to enoxaparin. The higher 
medication costs with fondaparinux relative to enoxaparin might be due to the price of 
outpatient prophylaxis with fondaparinux. This price, which is paid by patients after hospital 
discharge, is considerably higher than the inpatient price of fondaparinux (NOK108.59 11 vs 
NOK40.64 12). In order to test the impact of lower prices for outpatient prophylaxis with 
fondaparinux, we reduce this price by 10% to 20%. 
Results  
Table 5.2 presents the results of the sensitivity analyses on enoxaparin price (inpatient). and 
on fondaparinux price (outpatient) for the extended prophylaxis with fondaparinux and 
                                                 
11 Wholesale price; package of 20x0.5ml syringes. 
12 LIS price 
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enoxaparin. Please notice that in the Table, the results of the different sensitivity analyses are 
only reported for the cost difference between fondaparinux and enoxaparin.  
 
Table 5.2 Sensitivity analyses:  
VTE-related cost difference between fondaparinux and enoxaparin, per patient, NOK 
Extended prophylaxis  Follow-up time 
 Discharge Day 30 Day 90 Year 1 Year 5
THR Base case (enoxaparin, NOK8) - 1 469 1 266 1 186 905
 Enoxaparin price: NOK13.50 - 1 400 1 197 1 117 836
 Fondaparinux price, outpatient: -10% - 1 954 1 663 1 543 1 129
 Fondaparinux price, outpatient: -20% - 1 073 870 789 508
HFS Base case (enoxaparin, NOK8) - 1 051 843 704 208
 Enoxaparin price: NOK13.50 - 992 784 645 149
 Fondaparinux price, outpatient: -10% - 834 626 487 -9
 Fondaparinux price, outpatient: -20% - 617 409 269 -226
 
A price increase of enoxaparin to NOK13,50 reduces the cost difference between enoxaprin 
and fondaparinux. For example, following TKR at day 30 the cost difference between the two 
drugs is NOK1.469 in the main analysis (base case), while after the price increase this 
difference is reduced to NOK1.400. However, enoxaparin is still the lower cost treatment 
alternative compared with fondaparinux. 
Changing the price of outpatient treatment with fondaparinux has a positive impact on the 
cost difference between the two drugs especially after hip fracture surgery. A 10% reduction 
in the price of fondaparinux, makes fondaparinux cost saving by NOK9 compared to 
enoxaparin over a period of 5 years, while a 20% price reduction results in cost savings with 
fondaparinux by NOK226.  
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6. Discussion  
Our analyses were based on statistics from Norwegian National Register of Hospital Patients 
(NPR), which included 55.000 patients who underwent major orthopaedic surgery from 1999 
to 2001. Of these patients, 51.555 were selected in the analysis. The main model used in the 
analysis is a “core” model that has been developed to examine the cost-effectiveness of 
prophylaxis with fondaparinux versus enoxaparin in patients undergoing major orthopaedic 
surgery. All cost estimates in the model were based on the Norwegian unit costs, i.e. DRG-
costs for hospital stays and other relevant costs for year 2004.  
Short-term prophylaxis 
The results from the clinical outcomes indicate that in general, fondaparinux is the more 
effective drug in terms of preventing VTE-events both for the short-term prophylaxis 
compared to enoxaparin in all time periods. Compared with enoxaparin, short-term 
prophylaxis with fondaparinux is expected to avoid additional 194 DVT-events per 10.000 
patients following total knee replacement, 146 events following total hip replacement and 249 
events following hip fracture surgery by day 90 after surgery. These figures include 17 deaths 
after total knee replacement, 8 deaths after total hip replacement and 33 deaths after hip 
fracture surgery. 
In Norway, around 18.330 major orthopaedic surgeries are performed every year. Of these 
surgeries, 10% are total knee replacements, 40% total hip replacements and 50% hip fracture 
surgeries. This means that using fondaparinux instead of enoxaparin after these surgeries 
would prevent additional 371 VTE-events, including 39 deaths (fatal PE) per year in 
Norway13.  
The results from our analysis indicate that short-term prophylaxis with fondaparinux is more 
cost-effective in terms of preventing VTE-events compared to enoxaparin. From day 30 
onward, fondaparinux is cost saving after the three orthopaedic surgeries. Fondaparinux is 
also highly cost saving with respect to incremental costs per VTE avoided, VTE-related 
deaths avoided and costs per life-year gained, with benefits growing over time.  
 
                                                 
13 Based on the distribution of the three surgeries in our data set. 
SNF Report No. 1/05 
 31
Extended prophylaxis 
Compared to enoxaparin, extended prophylaxis with fondaparinux is expected to prevent 
additional 217 VTE-events (including 9 deaths) per 10.000 patients after total hip 
replacement, and additional 273 VTE-events (including 110 deaths) after hip fracture surgery 
by day 90.  
Of the total number of 18.330 major orthopaedic surgeries performed every year in Norway, 
16.500 surgeries are hip replacements and hip fracture surgeries. Extended prophylaxis with 
fondaparinux would avoid additional 409 VTE-events, including 107 deaths, per year 
compared to enoxaparin after total hip replacement and hip fracture surgery.  
In the case of extended prophylaxis, fondaparinux is the higher cost alternative relative to 
enoxaparin, but the cost difference decreases over time. For example, the cost difference 
between the two drugs at 30 days follow-up time is NOK1.051 after hip fracture surgery, 
while at 5 years follow-up time this difference is expected to be NOK208.  
Our results show that the costs per avoided VTE-event, cost per death avoided and cost per 
life-year gained are higher after total hip replacement than hip fracture surgery. For instance, 
by day 90, the incremental cost per avoided VTE-event is estimated to approximately 
NOK58.400 after total hip replacement and NOK30.800 after hip fracture surgery. Over a 
period of 5 years, the incremental cost per death avoided following total hip replacement is 
expected to be around NOK974.000, while the incremental cost per life-year gained is around 
NOK72.300. The incremental cost per death avoided following hip fracture surgery is 
expected to be around NOK18.900, while cost per life-year gained is only NOK2.800. There 
could be several reasons for why these costs are higher after total hip replacement. First, 
fondaparinux avoids more VTE-events, especially fatal PE, after hip fracture surgery 
compared to total hip replacement. Second, the length of stay in hospital by readmissions is 
higher among patients with total hip replacement than hip fracture surgery.  
New therapies usually involve higher costs than current therapies. This is also the case for 
extended prophylaxis with fondaparinux. Health authorities or hospitals have limited budgets 
and have to consider the effectiveness of the new therapies relative to the higher costs 
involved. In US, costs per death avoided or life-year gained below $50.000-60.000 are 
considered “acceptable” for the value of a life-year gained (e.g. Owens, 1998; Kanis et al., 
2002). A recent study in Norway suggests GDP per capita (approximately NOK350.000) as a 
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measure for the value of one additional life-year gained (Kristiansen, 2003). Given these 
values, fondaparinux is clearly cost-effective. As seen above, the incremental cost per life-
year gained with fondaparinux after hip fracture surgery is only NOK19.000 at day 30 and 
NOK2.800 five years after surgery. The same reasoning applies for total hip replacement. 
Study perspective 
In the end, this study is undertaken from the perspective of healthcare payers in Norway and 
does not consider the societal perspective. The economic gains of avoided VTE-events for the 
society (that is cost savings related to hospitalisation of patients with VTE), and benefits such 
as utility of the people who stay healthy because of the treatment by fondaparinux are not 
included in the present study.  
7. Conclusion 
In conclusion, short-term prophylaxis with fondaparinux is more effective than enoxaparin in 
preventing VTE-events after total knee and hip replacement, and hip fracture surgery. 
Extended prophylaxis with fondaparinux demonstrates even greater efficacy in preventing 
VTE-events. Finally, using fondaparinux instead of enoxaparin is a cost-effective strategy. 
Short-term prophylaxis with fondaparinux is also highly cost saving with respect to 
incremental costs per VTE-event avoided, VTE-related deaths avoided and costs per life-year 
gained, with benefits growing over time.  
The sensitivity analysis conducted on enoxaparin price confirmed the robustness of our 
results. However, for the extended prophylaxis, the results were sensitive to price reductions 
of outpatient prophylaxis with fondaparinux.  
SNF Report No. 1/05 
 33
References 
Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. “Fondaparinux compared with enoxaparin 
for the prevention of venous thromboembolism after elective major knee surgery”. The 
Pentamaks Study. N Eng J Med, 2001; 345 (18): 1305-1310. 
Bergqvist D et al. ”Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous 
thromboembolism after total hip replacement”. N Engl J Med, 1996; 335 (10):696-700. 
Bergqvist D, Jendteg S, Johansen L, Persson U, Odegaard K. Cost of long-term complications 
of deep venous thrombosis of the lower extremities: an analysis of a defined patient 
population in Sweden. Ann Intern Med 1997; 126: 454-457. 
Bjorvatn A, Kristiansen B. “Cost-effectiveness of fondaparinux vs enoxaparin as venous 
thromboembolism prophylaxis in Norway”. 2003; SNF Report No. 13/03. Institute for 
Research in Economics and Business Administration (SNF), Bergen, Norway. 
Bjorvatn A, Kristiansen B. “Fondaparinux Sodium Compared with Enoxaparin Sodium – A 
Cost-Effectiveness Analysis”. Am J Cardiovasc Drugs, 2005; 5 (2): 121-130. 
Braithwaite RS, Col NF, and Wong JB. “Estimating hip fracture morbidity, mortality and 
costs”. J Am Geriatr Soc, 2003; 51 (3):364-370. 
Clagett GP, Anderson FA Jr, Geerts W, et al. “Prevention of venous thromboembolism” 
Chest, 1998; 114: 531S-560S. 
Colwell CW, Collis DK, Paulson R, et al. “Comparison of enoxaparin and warfarin for the 
prevention of venous thromboembolic disease after total hip arthroplasty: Evaluation during 
hospitalization and three months after discharge”. J Bone Joint Surg Am,1999; 81-A:932-940. 
Dahl OE, Andreassen G, Aspelin T, Müller C, Mathiesen P, Nyhus S et al. “Prolonged 
thromboprophylaxis following hip replacement surgery - Results of a double-blind, 
prospective, randomized, placebo-controlled study with daltaparin (Fragmin)“. Thromb 
Haemost, 1997; 77: 26 - 31. 
Dahl OE, Gudmundsen TE, Haukeland L. “Late occurring clinical deep vein thrombosis in 
joint-operated patients”. Acta Orthop Scand, 2000; 71 (1): 47-50. 
SNF Report No. 1/05 
 34
Dahl OE, Pleil AM. Investment in prolonged thromboprophylaxis with dalteparin improves 
clinical outcomes after hip replacement“. Thromb Haemost, 2003; 1: 1-11.  
Das SK, Cohen AT, Edmonson RA, Melissari E, Kakkar VV. “Low-molecular-weight 
heparin versus warfarin for prevention of recurrent venous thromboembolism: A randomized 
trial“. World J Surg, 1996; 20:521-527. 
Davies L, Richardson GA, and Cohen AT. “Economic evaluation of enoxaparin as 
postdischarge prophylaxis for deep vein thrombosis (DVT) in elective hip surger”y. Value 
Health, 2000; 3 (6):397-406. 
Devlin JW et al. ”Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis 
against venous thrombosis after major trauma”. Pharmacotherapy, 1998;18 (6):1335-1342. 
Dranitsaris G, Kahn SR, Stumpo C, Paton TW, Martineau J, Smith R, Ginsberg JS. 
“Pharmacoeconomic Analysis of Fondaparinux for the Prevention of Thromboembolic Events 
in Orthopedic Surgery Patients”. Am J Cardiovasc Drugs, 2004; 4(5): 325-333. 
Drummond M et al. ”Economic evaluation of standard heparin and enoxaparin for 
prophylaxis against deep vein thrombosis in elective hip surgery”. Br J Surg, 1994; 81 
(12):1742-1746. 
Eikelboom JW, Quinlan DJ, and Douketis JD. “Extended-duration prophylaxis against venous 
thromboembolism after total hip or knee replacement: a meta-analysis of the randomised 
trials”. Lancet, 2001; 358 (9275): 9-15. 
Eriksson BI, Lassen MR, Turpie AGG. ”Fondaparinux compared with enoxaparin for the 
prevention of venous thromboembolism after hip-fracture surgery”, The Penthifra Study. The 
New England Journal of Medicine, 2001; 345 (18): 1298-1304. 
Eriksson BI, Bauer KA, Lassen MR, Turpie AGG. ”Duration of Prophylaxis Against Venous 
Thromboembolism with Fondaparinux after Hip Fracture Surgery”, The Penthifra Plus Study. 
Arch Intern Med, 2003; 163: 1337-1342. 
Falch JA, Kaastad TS, Bøhler G, Espeland J, Sundsvold OJ. Secular increase and 
geographical differences in hip fracture incidence in Norway. Bone 1993; 14: 643-645. 
SNF Report No. 1/05 
 35
Finsen, V. “Tromboseprofylakse ved ortopedisk kirurgi”. Tidskrift for den norske 
lægeforningen 2000; 120: 565-7. 
Geerts WH, Heit JA, Clagett GP, Pineo GF, Clowell CW, Anderson FA Jr, Brownell 
Wheeler, H. “Prevention of venous thromboembolism”. Chest, 2001; 119:132S-175S. 
Ginsberg JS, Gent M, Turkstra T, Buller HR, MacKinnon B, Magier D, Hirsh J. 
“Postthrombotic syndrome after hip or knee arthroplasty: A cross-sectional study”. Arch 
Intern Med, 2000; 160:669-672. 
Gordois A, Posnett J, Borris L, Bossuyt P, Jönsson B, Levy E, de Pouvourville G. “The cost-
effectiveness of fondaparinux compared with enoxaparin as prophylaxis against 
thromboembolism following major orthopedic surgery”. J Thromb Haemost 2003; DOI: 
10.1046/j.1538-7933.2003.00396.x. 
Hansson PO, Sorbo J, Eriksson H. “Recurrent venous thromboembolism after deep vein 
thrombosis: Incidence and risk factors”. Arch Intern Med, 2000; 160:769-774. 
Hawkins DW, Langley PC, and Krueger KP. “Pharmacoeconomic model of enoxaparin 
versus heparin for prevention of deep vein thrombosis after total hip replacement. Am J 
Health Syst Pharm, 1997; 54 (10):1185-1190. 
Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. ”Ardeparin sodium for 
extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee 
replacement: A randomized, double-blind, placebo-controlled trial”. Ann Intern Med, 
2000;132:853-861. 
Hillson SD and Rich EC. “Two strategies for prophylaxis of fatal postoperative pulmonary 
embolism. Cost-effectiveness analysis”. Int J Technol Assess Health Care, 1990; 6 (3):470-
479.  
Hull R, Delmore T, Carter C, et al. “Adjusted subcutaneous heparin versus warfarin sodium in 
the long-term treatment of venous thrombosis”. N Eng J Med, 1982; 306:189-194. 
Kanis JA, Johnell O, Oden A, De laet C, Oglesby A, Johnsson B. “Intervention thresholds for 
osteoporosis”. None, 2003; 31: 26-31. 
SNF Report No. 1/05 
 36
Kearon C. “Duration of venous thromboembolism prophylaxis after surgery”. Chest, 2000; 
124: 386S-392S. 
Kristiansen, IS. “Verdien av liv og helse – Hvor mye bør samfunnet være villige til å betale 
for helseforbedringer”. Skridtserie 2003:6, Helseøkonomisk forskningsprogram, Universitetet 
i Oslo, Oslo. 
Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. “Need for long-term 
anticoagulant treatment in symptomatic calf-vein thrombosis”. Lancet, 1985; 2:515-518. 
Lassen MR, Bauer KA, Eriksson BI, Turpie AGG. “Postoperative fondaparinux versus 
postoperative enoxaparin for prevention of venous thromboembolism after elective hip 
replacement surgery: a randomized double-blind comparison”, The EPHESUS study. Lancet, 
2002: 359:1715-1720. 
Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. ”The incidence of symptomatic venous 
thromboembolism during and after prophylaxis with enoxaparin”. Arch Intern Med, 1998; 
158:873-878. 
Levin LA, Bergqvist D. ”Cost effectiveness of desirudin compared with a low molecular 
weight heparin in the prevention of deep vein thrombosis after total hip replacement surgery”. 
Pharmacoeconomics, 2001;19 (5 Pt 2):589-597. 
Levin LA, Horst M, and Bergqvist D. “Economic evaluation of desirudin vs heparin in deep 
vein thrombosis prevention after hip replacement surgery”. Pharmacoeconomics, 1998; 13 (1 
Pt 2):111-118. 
Lloyd A, et al. ”Economic evaluation of the use of nadroparin calcium in the prophylaxis of 
deep vein thrombosis and pulmonary embolism in surgical patients in Italy”. 
Pharmacoeconomics, 1997; 12 (4):475-485. 
Lloyd AC, et al. ”Economic evaluation of the use of enoxaparin for thomboprophylaxis in 
acutely ill medical patients”.  Journal of drug Assessment, 2001; 4:145-159. 
Lubinus P, Klauser W. ”Mortality after total hip replacement due to fatal pulmonary 
embolism”. 2001; Abstract (114). 1st SICOT / SIROT Annual International Conference, Paris. 
SNF Report No. 1/05 
 37
Lundkvist J, Bergqvist D, Jönsson B. ”Cost-effectiveness of fondaparinux vs. enoxaparin as 
venous thromboembolism prophylaxis in Sweden. Eur J Health Econom, 2003; 4:254-262. 
Lu-Yao GL, Baron JA, Barrett JA, Fisher ES. “Treatment and survival among elderly 
Americans with hip fractures: A population-based study”. Am Journal of Public Health, 1994; 
84:1287-1291. 
Manganelli D, et al. ”Prolonged prophylaxis with unfractioned heparin is effective to reduce 
delayed deep vein thrombosis in total hip replacement. Respiration, 1998; 65 (5):369-374. 
Nicolaides AN and Bosanquet N. “Cost-effectiveness of desirudin in the prevention of the 
thromboemebolism complications of surgery”. Journal of drug Assessment, 1999; 2:353-364. 
Norwegian Medicine Agency. “The Norwegian guidelines for pharmacoeconomic analysis”, 
2003, Oslo .  
Norwegian National Register of Hospital Patients. National Inpatient Care Statistics. Samdata 
Report, SINTEF Unimed, Trondheim. 
Oster G, Tuden RL, Colditz GA. ”A cost-effectiveness analysis of prophylaxis against deep-
vein thrombosis in major orthopaedic surgery”. JAMA, 1987a, 257: 203-208. 
Oster G, Tuden RL, and Colditz GA. “Prevention of venous thromboembolism after general 
surgery. Cost-effectiveness analysis of alternative approaches to prophylaxis”. Am J Med, 
1987b; 82 (5):889-899. 
Owens DK. ”Interpretation of cost-effectiveness analyses”. [Editorial]. J Gen Intern Med, 
1998; 13: 716-717. 
Policy Analysis Inc (PAI). Outcomes and costs of prophylaxis against venous 
thromboembolism in patients undergoing major orthopedic surgery: Final technical report. 
Policy Analysis Inc, Massachusetts, USA. 2001. 
Pini M, Aiello S, Manotti C, et al. “Low molecular weight heparin versus warfarin in the 
prevention of recurrences after deep vein thrombosis”. Thromb Haemost, 1994; 72:191-197. 
SNF Report No. 1/05 
 38
Planes A, Vochelle N, Darmon JY, Fagola M, Huet Y. “Risk of deep venous thrombosis after 
hospital discharge in patients undergoing total hip replacement. Double-blind randomised 
comparison of enoxaparin versus placebo”. Lancet, 1996; 348: 224 -228.  
Posnett I, Gordis A. ”Cost-effectiveness of fondaparinux vs enoxaparin as prophylaxis against 
venous thromboembolism following orthopaedic surgery”. Value in Health, 2002; 5(6):444-. 
Prandoni P, Lensing AWA, Cogo A, et al. “The long-term clinical course of acute deep 
venous thrombosis”. Ann Intern Med, 1996; 125:1-7. 
Schulman S, Rhedin AS, Lindmarker P, et al. “A comparison of six weeks with six months of 
oral anticoagulant therapy after a first episode of venous thromboembolism”. N Eng J Med, 
1995; 332:1661-1665. 
Siragusa S, Beltrametti C, Barone M, Piovella F. “Clinical course and incidence of post-
phlebitic syndrome after asymptomatic deep vein thrombosis: Results of a cross-sectional 
epidemiological study”. Minerva Cardioangiol, 1997; 45:57-66. 
Statistics Norway. “Norwegian Population Statistics”, 2004, Oslo. 
Sullivan SD et al. “Cost-effectiveness of fondaparinux compared with enoxaparin as 
prophylaxi against venous thromboembolsim in patients undergoing major orthopedic 
surgery”. Blood, 2002; (Abstract) 100 (11): 871a. 
Sullivan SD, Davidson BL, Kahn SR, Muntz JE, Oster G, Raskob G. “A Cost-Effectiveness 
Analysis of Fondaparinux Sodium Compared with Enoxaparin as Prophylaxis Against 
Venous Thromboembolism –Use in Patients Undergoing Major Orthopaedic Surgery”. 
Pharmacoeconomics 2004; 22 (9): 605-620. 
Sullivan SD, Kwong L. “Extended prophylaxis treatment with fondaparinux is cost effective 
compared with enoxaparin after hip fracture surgery”. Blood, 2003; (Abstract) 102 (11): 510b. 
Sullivan SD, Kwong L. “The incremental cost per life-year saved of extended prophylaxis 
with fondaparinux versus enoxaparin after hip fracture surgery”. Blood, 2003; (Abstract) 102 
(11):502a. 
SNF Report No. 1/05 
 39
Szucs TD and Schramm W. “The cost-effectiveness of low-molecular-weight heparin vs 
unfractionated heparin in general and orthopaedic surgery: an analysis for the German 
healthcare system”. Pharmacol Res. 1999;40 (1):83-89. 
The National Insurance Services. “Price list”, 2004, Oslo. 
Todd CJ et al. ”Differences in mortality after fracture of hip: the east Anglian audit”. BMJ, 
1995; 310 (6984):904-908.  
Turpie AGG, Bauer KA, Eriksson MD, Lassen MR. “Fondaparinux versus Enoxaparin for the 
Prevention of Venous Thromboembolism in Major Orthopedic Surgery: A Meta-analysis of 4 
Randomized Double-blind Studies”. Arch Intern Med, 2002a; 162: 1833-1840. 
Turpie AGG, Bauer KA, Eriksson BI, Lassen MR. “Postoperative fondaparinux versus 
postoperative enoxaparin for prevention of venous thromboembolism after elective hip 
replacement surgery: a randomized double-blind trial”, The PENTATHLON 2000 Study. 
Lancet, 2002b; 359:1721-1726. 
Wade WE, Spruill WJ, Leslie RB. “Cost Analysis of Fondaparinux Versus Enoxaparin as 
Venous Thromboembolism Prophylaxis in Hip Fracture Surgery”. American Journal of 
Therapeutics, 2004; 11(3): 194-198. 
SNF Report No. 1/05 
 40
Appendix A: Estimation of model probabilities 
This appendix is a summary of estimation of the model probabilities used in the fondaparinux 
extended prophylaxis model presented in “Cost-effectiveness of extending prophylaxis with 
fondparinux against venous thromboembolism in patients undergoing hip fracture surgery and 
total hip replacement (2003)”.  
Risk of Subclinical DVT  
 
Patients are assumed to be at risk of developing a thrombus through Day 30 following 
surgery. The rate of subclinical DVT at Day 30 was based on the rate of venographically 
detected DVT from several different trials and published meta-analyses. Rates of subclinical 
DVT and PE at Day 30 were available from extended prophylaxis trial data for HFS patients 
using fondaparinux (Penthifra Plus, Eriksson 2003). Rates were available from the literature 
for THR patients using LMWH/heparin (Eikelboom, 2001). In cases where the subclinical 
rate was not available, an estimate was constructed using relative risks on known subclinical 
rates, ie assuming that the relative benefit of extending prophylaxis with a given drug will be 
the same in either the HFS or THR population.     
 
 
• Estimation of subclinical DVT rates at day 30 in patients undergoing HFS: 
 
Prophylaxis All VTE Clinical VTE Subclinical DVT   
Fondaparinux 7-day 35% 2.73% 32.27% 
Fondaparinux 28-day 1.44% 0.31% 1.14% 
Enoxaparin 7-day   53.38% 
Enoxaparin 28-day   22.10% 
 
 
Among HFS patients receiving short-term duration prophylaxis with fondaparinux, the rate of 
subclinical DVT at Day 30 (32.3%) was obtained by subtracting the rate of symptomatic 
events (2.7%) from the all VTE rate (35%). The rate of subclinical DVT for extended 
prophylaxis (1.1% ) was obtained similarly (Eriksson 2003).   
 
For HFS patients receiving short term duration prophylaxis with enoxaparin, the rate of  
subclinical  DVT at day 30 (53.4%) was estimated by adjusting the corresponding rate for 
HFS patients receiving short term duration fondaparinux prophylaxis (32.3%) , using the 
relative risk ratio of  VTE for fondaparinux versus enoxaparin in HFS patients at Day 30  
(RR= 0.60) (Gordois, 2003). The rate of subclinical DVT at day 30 among HFS patients 
Apply RR= 0.60
Apply RR= 0.41
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receiving extended duration prophylaxis with enoxaparin was calculated by multiplying the 
rate of subclinical DVT calculated above by the relative risk of subclinical DVT for short 
term duration enoxaparin versus extended enoxaparin (RR= 0.41) (Eikelboom 2001), ie 
assuming that the benefit of extending prophylaxis with enoxaparin that was observed in 
patients undergoing total hip replacement would be the same in patients undergoing surgery 
for hip fracture. 
 
• Estimation of subclinical DVT rates at day 30 in patients undergoing THR: 
 
 
 
Among THR patients receiving enoxaparin, the rate of subclinical DVT at Day 30 was based 
on data from a meta-analysis of extended prophylaxis for THR patients using LMWH 
/heparin (Eikelboom 2001).  The rate of subclinical DVT at Day 30 for the short-term 
duration prophylaxis group was 18.6% versus 7.7% for the extended duration prophylaxis 
group. 
 
For THR patients receiving short term duration prophylaxis with fondaparinux, the rate of 
subclinical DVT at day 30 (10.9%) was similarly estimated by adjusting the rate of subclinical 
DVT for patients receiving short term duration prophylaxis with  enoxaparin (18.6%) using 
the relative risk of VTE for fondaparinux versus enoxaparin in THR patients at Day 30 (0.59) 
as estimated by Gordois when both drugs were administered for a median duration of 7-days 
(Gordois, 2003). For THR patients receiving extended duration prophylaxis with 
fondaparinux, the rate of subclinical DVT at Day 30 (0.45 %) was calculated by multiplying 
the estimated rate of subclinical DVT at Day 30 for THR patients receiving short term 
duration prophylaxis described above (10.9%) by the relative risk of all VTE 14 for 
fondaparinux short term duration prophylaxis versus extended prophylaxis among HFS 
patients (0.04) (Eriksson, 2003) ie assuming that the benefit of extending prophylaxis with 
fondaparinux that was observed in patients undergoing surgery for hip fracture would be the 
same in patients undergoing total hip replacement. 
 
 
                                                 
14 Conservative proxy for the relative risk for subclinical DVT 
Prophylaxis All VTE Clinical VTE Subclinical DVT   
Fondaparinux 7-day   10.95% 
Fondaparinux 28-day   0.45% 
Enoxaparin 7-day   18.60% 
Enoxaparin 28-day   7.70% Apply RR= 0.59
Apply RR= 0.04
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Risk of clinical VTE 
 
Clinical VTE at Day 7:  
 
The rate of clinically symptomatic VTE at day 7 was based on published trial data.   
 
For HFS patients, the rate for fondaparinux of 0.68% is from the PenthifraPlus trial data; this 
compares to the rate of 1.56% for enoxaparin (LMWH), which was derived by adjusting this 
rate using the relative risk of all VTE at Day 11 for enoxaparin versus fondaparinux ((0.44) 
when both drugs were administered for a median duration of 7-days in patients undergoing 
hip fracture surgery (Eriksson 2001).   
For THR patients, the rate for enoxaparin (0.69%) has been estimated from the literature, 
using the studies included in the meta-analysis published by Eikelboom, for which such rates 
were available (Eikelboom, 2001, Bergqvist 1996, Dahl 1997, Lassen 1998, Manganelli 1998, 
Heit 2000). The rate for fondaparinux (0.39%) was then derived by adjusting this rate using 
the relative risk of all VTE at Day 11 for enoxaparin versus fondaparinux (0.57) when both 
drugs were administered for a median duration of 7-days in patients undergoing total hip 
replacement (Lassen 2002, Turpie 2002). 
 
 
Clinical VTE Day 7-Day 30: 
 
The rates of clinical VTE for HFS patients receiving fondaparinux and THR patients 
receiving enoxaparin were taken directly from extended prophylaxis trial data. For the rates of 
clinical VTE for HFS patients receiving enoxaparin and THR patients receiving fondaparinux, 
an estimate was constructed similarly as above using relative risks on known clinical rates, ie 
assuming that the relative benefit of extending prophylaxis with a given drug will be the same 
in either the HFS or THR population 
Among HFS patients receiving fondaparinux, the rate of clinical DVT at Day 30 was 2.7% for 
short term duration prophylaxis and 0.3% for extended prophylaxis (Eriksson 2003). 
For HFS patients receiving short term duration prophylaxis with enoxaparin, the rate of 
clinical VTE at day 30 (4.5%) was estimated by adjusting the rate of symptomatic VTE at 
Day 30 for HFS patients receiving short term duration fondaparinux prophylaxis (2.7%) by 
using the relative risk ratio of VTE for fondaparinux versus enoxaparin in HFS patients at 
Day 30 (0.60) (Gordois, 2003). The rate of clinical VTE for HFS patients receiving extended 
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duration prophylaxis with enoxaparin (1.5%) was estimated by adjusting the rate for the short 
term group (4.5%) by the relative risk for symptomatic VTE (0.33) for short-term duration 
enoxaparin versus extended enoxaparin  (Eikelboom 2001). 
 
Estimation of clinical event rates up to day 30 in HFS: 
 
Prophylaxis Clinical VTE Day  7 Clinical VTE Day 30   
Fondaparinux 7-day 0.68 % 2.73 % 
Fondaparinux 28-day 0.68 % 0.31 % 
Enoxaparin 7-day 1.56 % 4.51 % 
Enoxaparin 28-day 1.56 % 1.49 % 
 
 
Among THR patients receiving enoxaparin, the rate of clinical DVT at Day 30 was based on 
data from the meta-analysis of extended prophylaxis using heparin (Eikelboom 2001). The 
rate of clinical DVT at Day 30 for the short term duration prophylaxis group was 4.3% versus 
1.4% for the extended duration prophylaxis group. 
Among the THR population, the rate of clinical VTE at day 30 for patients on short term 
duration fondaparinux prophylaxis (2.5%) was derived by multiplying the rate of clinical VTE 
at Day 30 among THR patients in the short term duration enoxaparin group (4.3%) by the 
relative risk of VTE for fondaparinux versus enoxaparin in THR patients at Day 30 (0.59) as 
estimated by Gordois when both drugs were administered for a median duration of 7-days 
(Gordois, 2003).  Then, the rate of clinical VTE in the extended duration group (0.28%) was 
estimated by multiplying the rate for the short term duration group described above (2.5%) by 
the relative risk of symptomatic VTE for fondaparinux short term duration prophylaxis versus 
extended prophylaxis (0.11) among HFS patients (Eriksson, 2003).  
Estimation of clinical event rates up to day 30 in THR: 
 
 
 
  
 
 
 
Clinical VTE Day 30-Day 90 
 
The study of the temporal pattern of VTE events conducted by White et al. was used to 
calculate the ratio of the number of clinical events from day 60-day 90 over the number of 
clinical events from day 7 to day 30 (White, 1998). Data for patients receiving no extended 
Prophylaxis Clinical VTE Day 7 Clinical VTE Day 30 
Fondaparinux 7-day 0.39 % 2.52 % 
Fondaparinux 28-day 0.39 % 0.28 % 
Enoxaparin 7-day 0.69 % 4.29 % 
Enoxaparin 28-day 0.69 % 1.42 % 
Apply RR= 0.44  /RR=0.60 
Apply RR= 0.33
Apply RR= 0.57 /RR= 0.59
Apply RR= 0.11
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prophylaxis were extrapolated to the day30- day 90 time period by applying this ratio to the 
actual rate of clinical events reported from day 7- day 30. A contingent probability was then 
constructed to calculate the probability of a clinical VTE at day 90, given the probability of a 
subclinical VTE at day 30. This probability was then used to estimate the clinical rates at day 
90. A similar approach was made for both HFS and THR and a contingent probability was 
thus calculated separately for the HFS and THR patient populations.   
 
Risk to develop clinical symptomatic VTE after day 30 (contingent probability): 
  HFS THR 
All VTE at Day 30 0,35000 0,18600 
Clinical DVT at Day 30 0,02727 0,0429 
Clinical DVT rate at Day 90 0,01251 0,01968 
Total DVT/PE contingent probability 0,0388 0,1058 
 
 
 
Proportion of Clinical DVT/PE 
 
Due to the limited number of individual events (DVT or PE) reported, the event rates have 
been combined into a clinical VTE rate. In order to assess the individual consequences of 
DVT and PE, the clinical VTE rate was proportioned between DVT and PE based on the 
following ratios, calculated using larger populations (It is assumed to differ only by type of 
orthopedic surgery and was not considered to be dependent on type of prophylaxis). In the 
HFS patient population, the proportion of VTE that was allotted to DVT was 37.5% versus 
62.5% for PE (Eriksson 2001, Eriksson 2003). In the THR patient population, the proportion 
was 71.3% for DVT and 28.7% for PE (Colwell 1999, Leclerc 1998). 
 
Major Bleeding   
 
The risks of major haemorrhage (defined as 1/ fatal bleeding, bleeding in a critical organ, 
bleeding leading to re-operation and 2/ overt bleeding associated with a bleeding index>215) 
following prophylaxis were taken from trial data of short-term prophylaxis enoxaparin versus 
fondaparinux (Lassen  2002, Turpie  2002, Eriksson  2001) as well as trial data of extended 
duration prophylaxis (Eriksson 2003). The model assumed no difference between active 
groups in the extended phase of prophylaxis (see table 2).    
                                                 
15 Number of units of packed red blood cells or whole blood transfused, plus [prebleeding minus postbleeding 
hemoglobin values in g/dl] 
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False-Positive Clinical DVT & PE  
 
A false-positive rate was applied to the decision tree model to assess patients incorrectly 
suspected of having a DVT (10%) or PE (2%).  Rates are modal values taken from the 
literature (Davies 2000, Devlin 1998, Drummond 1994, Hawkins 1997, Hillson 1990, Levin 
1998, Levin 2001, Lloyd 1997, Lloyd 2001, Menzin 1995, Nicolaides 1999, O'Brien 1994, 
Oster 1987a, Oster 1987b, Pechevis 2000, Szuchs 1999). The false-positive rates were 
assumed to be the same for both surgery groups and type of prophylaxis.   
 
 
Risk of Recurrent VTE    
 
The risk of recurrent VTE was calculated using data from a long-term follow-up study of 
patients with objectively verified symptomatic DVT (Prandoni 1996). The incidence over five 
years of recurrence for the overall population was 21.5%, while the relative risk of recurrence 
for patients who had undergone major orthopedic surgery was 0.21. In order to estimate the 
risk of recurrence in the THR and HFS populations, the overall incidence was multiplied by 
the relative risk to get the estimate of 4.5%. 
 
Since the above study did not report the recurrence rate for the first 90 days following a VTE, 
data from other treatment trials were used to estimate the risk of recurrence during treatment 
(2.6%) (Hull 1982a, Hull. 1982 b, Lagerstedt 1985, Pini 1994, Schulman 1995, Das1996). 
This rate was also adjusted using the relative risk of 0.21 from above; this resulted in a 
recurrence rate of 0.6% for the first 90 days and 3.9% for the period from day 90 to year 5. 
The latter recurrence rate was apportioned according to the temporal pattern observed in the 
long-term recurrence study (Prandoni 1996). 
 
Risk of Post-Thrombotic Syndrome    
 
The probability of developing PTS for patients who had a clinical VTE during first 90 days 
(28% at 5 years) was based on data from a prospective study of the long-term clinical course 
of acute VTE over one, two and five years (Prandoni 1996). Among patients who had only a 
subclinical VTE, the risk of PTS (12%) was based on the weighted average incidence of PTS 
among orthopedic surgery patients with venographically detected DVT in two retrospective 
studies (Ginsberg 2000, Siragusa 1997). In all cases, the risk of PTS was assumed to begin 
after day 90 (see table 3). 
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Mortality 
   
The model accounts for the risk of fatal PE, and also for deaths from all other causes. The risk 
of fatal PE was assumed to differ only by type of orthopedic surgery and was not considered 
to be dependent on type of prophylaxis.  For THR patients having a PE, the risk of fatal PE 
(14.5%) was estimated using four large studies of VTE incidence (Pelligrini, LeClerc 1998, 
Colwell 1999, Heit 2000). Since literature-based estimates were not available for HFS, the PE 
fatality rate from the Pentifra and Penthifra Plus trial was used to estimate the risk of fatal PE 
in this group (64%) (Eriksson 2001, Eriksson 2003). 
 
Life expectancy 
 
For THR patients, life expectancy was assumed to be the same as in the general population 
matched for age and sex with the studied cohort (source: national statistics). Hip fracture is 
associated with substantial mortality and morbidity, and was reported to result in a 25% 
reduction in life expectancy (Braithwaite, 2003) and survival was adjusted in the HFS patients 
accordingly. 
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Tables 
 
Table 1.1   VTE-related probabilities / HFS 
Type of prophylaxis HFS Reference(s) 
Enoxaparin   
   Day 1-Day 7   
         Symptomatic VTE 0.0156 Calculation 
   Extended Prophylaxis   
        Symptomatic VTE before Day 30 0.0149 Calculation 
        Subclinical VTE - Day 7-Day 30  0.2210  
        Symptomatic DVT - Day 30-Day 90 0.0388 Calculation 
Fondaparinux   
   Day 1-Day 7   
        Symptomatic VTE 0.0068 Eriksson 2003 
   Extended Prophylaxis   
        Symptomatic VTE before Day 30 0.0031 Eriksson 2003 
        Subclinical VTE - Day 7-Day 30  0.0114 Eriksson 2003 
        Symptomatic DVT - Day 30-Day 90 0.0388 Calculation 
 
Table 1.2   VTE-related probabilities / THR 
Type of prophylaxis THR Reference(s) 
Enoxaparin   
   Day 1-Day 7   
       Symptomatic VTE 0.0069 Bergqvist 1996, Dahl 1997, Lassen 
1998, Manganelli 1998, Heit 2000 
(from Eikelboom 2001) 
   Extended Prophylaxis   
       Symptomatic VTE before Day 30 0.0142 Eikelboom 2001 
       Subclinical VTE - Day 7-Day 30  0.0770 Eikelboom 2001 
       Symptomatic DVT - Day 30-Day 90 0.1058 
Calculation 
Fondaparinux   
   Day 1-Day 7   
        Symptomatic VTE 0.0039 Calculation 
   Extended Prophylaxis   
          Symptomatic VTE before Day 30 0.0028 Calculation 
          Subclinical VTE - Day 7-Day 30  0.0045 Calculation 
          Symptomatic DVT - Day 30-Day 90 0.1058 Calculation 
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Table 2. Probabilities of major bleeding  
Bleeding index >21 
   
Other Major Bleeding2  
 
                     Fondaparinux Enoxaparin             Fondaparinux Enoxaparin
 7-day extended extended  7-day extended extended 
HFS       HFS       
Day 1-7 0,018 0,018 0,019 Day 1-7 0,004 0,004 0,004 
Day 8-30 0 0,018 0,018 Day 8-30 0,006 0,006 0,006 
THR    THR    
Day 1-7 0,026 0,026 0,016 Day 1-7 0,003 0,003 0,003 
Day 8-30 0 0,018 0,018 Day 8-30 0,006 0,006 0,006 
Sources: Lassen 2002, Turpie 2002, Eriksson 2001, Eriksson 2003 
1 overt bleeding associated with a bleeding index>216 
2 fatal bleeding, bleeding in a critical organ, bleeding leading to re-operation    
 
Table 3.   Other probabilities 
 Type of procedure 
Parameter HFS THR Reference(s) 
    
False-positive DVT 0.10 0.10 Davies 2000, Devlin 1998, Drummond 1994, 
Hawkins 1997, Hillson 1990, Levin 1998, Levin 
2001, Lloyd 1997, Lloyd 2001, Menzin 1995, 
Nicolaides 199, O'Brien 1994, Oster 1987a, 
Oster 1987b, Pechevis 2000, Szuchs 1999 
False-positive PE 0.02 0.02 Same as above 
Death             
       Due to fatal PE 0.64 0.0145 Leclerc 1998, Colwell 1999, Heit 2000, 
Pelligrini 1996Eriksson 2001, Eriksson, 2003 
       Due to recurrent VTE 0.1231 0.0279 Prandoni 1996 
       All other causes:   According to national statistics 
Post-thrombotic syndrome    
         Patients with clinical DVT or PE    
                  Day 90 to Year 1 0.1730 0.1730 Prandoni 1996 
                  Year 2 0.0550 0.0550 Prandoni 1996 
                  Year 3 + 0.0173 0.0173 Prandoni 1996 
         Patients with subclinical DVT    
                  Day 90 to Year 1 0.0722 0.0722 Ginsberg 2000, Siragusa 1997 
                  Year 2 0.0229 0.0229 Ginsberg 2000, Siragusa 1997 
               Year 3 + 0.0072 0.0072 Ginsberg 2000, Siragusa 1997 
Recurrent VTE    
         Day 1- day 30 0.0018 0.0018 Hansson 2000 
         Day 31-Day 90 0.0036 0.0036 Hansson 2000 
         Chronic phase (day 91- year 5) 0.0397 0.0397 Hansson 2000 
 
                                                 
16 Number of units of packed red blood cells or whole blood transfused, plus [prebleeding minus postbleeding 
hemoglobin values in g/dl] 
